< Back to Find a Trial

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients with Prodromal to Mild Alzheimer’s Disease (BN29552)

ID

NCT02670083

Condition Studied

Alzheimer's Disease

Phase

Phase III

Status

Closed

Intervention

Crenezumab

Principal Investigator

Adam Boxer, MD, PhD

[email protected]

415 - 476 - 0668

Please go to ClinicalTrials.gov for more information.